Reuters logo
BRIEF-Advaxis and Sellas announce licensing agreement for development of WT1 antigen-targeting immunotherapy
2017年2月27日 / 下午1点37分 / 9 个月前

BRIEF-Advaxis and Sellas announce licensing agreement for development of WT1 antigen-targeting immunotherapy

Feb 27 (Reuters) - Advaxis Inc

* Advaxis and Sellas announce licensing agreement for development of WT1 antigen-targeting immunotherapy

* Advaxis Inc- Advaxis will receive future payments of up to $358 million from Sellas if certain development, regulatory, and commercial milestones are met

* Advaxis Inc says advaxis will receive future payments of up to $358 million from Sellas if certain development, regulatory

* Under terms of collaboration, Advaxis will conduct all pre-clinical activities required for an Ind Filin

* Advaxis Inc says Sellas will be responsible for all clinical development and commercial activities

* Advaxis -after regulatory approval of product Sellas to pay Advaxis single-digit to low double-digit royalties based on worldwide net sales upon commercialization Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below